Dupilumab Treatment Effects in an Ethnically Diverse Population With Chronic Rhinosinusitis With Nasal Polyposis

Description

The central hypothesis of this study is that the addition of dupilumab treatment onto standard-of-care intranasal corticosteroids will improve patient-reported measures of disease activity and sense of smell in a cohort of mostly ethnical and racial minority patients with CRSwNP

Conditions

Chronic Rhinosinusitis With Nasal Polyps

Talk to us

Study Overview

On this page

Study Details

Study overview

The central hypothesis of this study is that the addition of dupilumab treatment onto standard-of-care intranasal corticosteroids will improve patient-reported measures of disease activity and sense of smell in a cohort of mostly ethnical and racial minority patients with CRSwNP

Dupilumab Treatment Effects in an Ethnically Diverse Population With Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)

Dupilumab Treatment Effects in an Ethnically Diverse Population With Chronic Rhinosinusitis With Nasal Polyposis

Condition
Chronic Rhinosinusitis With Nasal Polyps
Intervention / Treatment

-

Contacts and Locations

Bronx

Montefiore Medical Center, Bronx, New York, United States, 10461

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Patients with physician-diagnosed CRSwNP, with or without comorbid asthma that meet indication criteria for FDA-approved use of Dupilumab.
  • * Patients aged 18 years and older.
  • * Patient willing to provide consent to be a participant in the study.
  • * Patients with insurance that allows Dupilumab coverage or Dupilumab coverage obtained through "Dupixent MyWay Program"
  • * Age under 18
  • * Suspected or diagnosed allergic fungal rhinosinusitis.
  • * Suspected or diagnosed cystic fibrosis.
  • * Dupilumab coverage denied through insurance or "Dupixent MyWay Program"
  • * Patients who required a steroid taper in the preceding 30 days. However, patients on chronic steroids less or equal to 20 mg of prednisone daily, are eligible.
  • * Patients who were on a different biologic medication in the preceding 3 months.
  • * Patients with a diagnosis of EGPA/Churg-Strauss Syndrome
  • * Pregnant patients
  • * Patients with inverted papilloma growth

Ages Eligible for Study

18 Years to 99 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Montefiore Medical Center,

Golda Hudes, MD, PRINCIPAL_INVESTIGATOR, Montefiore Medical Center

Study Record Dates

2026-06